Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:39:13 EST Sat 06 Dec 2025
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 33 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-12-06 20:45U:ABTNews ReleaseUniversity of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives
2025-12-06 17:30U:TCRXNews ReleaseTScan Therapeutics Announces Positive Updated Data from the ALLOHA(TM) Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
2025-12-06 17:30U:FULCNews ReleaseFulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
2025-12-06 17:15U:PFENews ReleaseHYMPAVZI(TM) (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
2025-12-06 15:30U:BNTXNews ReleaseBioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
2025-12-06 14:00U:LEGNNews ReleaseLegend Biotech Highlights New CARVYKTI(TM) Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
2025-12-06 14:00U:GILDNews ReleaseKite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
2025-12-06 14:00U:GILDNews ReleaseKite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
2025-12-06 14:00U:EVAXNews ReleaseEvaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
2025-12-06 14:00U:ACLXNews ReleaseArcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
2025-12-06 13:51U:VWAVNews ReleaseTHE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
2025-12-06 13:51U:VPTDFNews ReleaseTHE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
2025-12-06 13:51U:ONCYNews ReleaseTHE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
2025-12-06 13:51U:GHVNFNews ReleaseTHE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
2025-12-06 13:51U:AVAINews ReleaseTHE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
2025-12-06 12:45U:HIRUNews ReleaseAMEEREX Signs MOU to Acquire 45.6 million-Ounce Silver-Gold Project in Nevada, Expanding Its North American Precious-Metals Portfolio
2025-12-06 12:17U:WSNews ReleaseWorthington Steel Issues Statement Regarding Klockner & Co SE
2025-12-06 11:00U:PRLDNews ReleasePrelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
2025-12-06 10:15U:AAPGNews ReleaseAscentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
2025-12-06 09:30U:TAKNews ReleaseProtagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
2025-12-06 09:30U:NRIXNews ReleaseNurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual M
2025-12-06 09:30U:JNJNews ReleaseEarlier use of CARVYKTI(TM) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
2025-12-06 09:30U:GMABNews ReleaseGenmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
2025-12-06 09:30U:COGTNews ReleaseCogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
2025-12-06 09:00U:VTRSNews ReleaseViatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
2025-12-06 08:30U:ADPTNews ReleaseAdaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ(TM) Data Driving Treatment Interventions at 2025 ASH Annual Meeting
2025-12-06 08:05U:ARVNNews ReleaseArvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
2025-12-06 08:00U:IRONNews ReleaseDisc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
2025-12-06 08:00U:COSTNews ReleaseCanada's Tenth Costco Business Centre is now open in East Gwillimbury
2025-12-06 08:00U:BEAMNews ReleaseBeam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
2025-12-06 08:00U:BCAXNews ReleaseBicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
2025-12-06 08:00U:APTOFNews ReleaseAptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
2025-12-06 07:01U:VRTXNews ReleaseVertex Presents New Data on CASGEVY(TM), Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions